Research graph
References from SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney. Local targets link to admitted publications; unresolved targets remain external evidence.
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension
10.1038/s41569-021-00559-8 · 2021 · External reference
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
10.1016/s0140-6736(16)31134-5 · 2016 · External reference
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(18)32225-6 · 2018 · External reference
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
10.1016/s0140-6736(21)01330-1 · 2021 · External reference
2018 ESC/ESH Guidelines for the management of arterial hypertension
10.1093/eurheartj/ehy339 · 2018 · External reference
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1812389 · 2019 · External reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015 · External reference
Empagliflozin and progression of kidney disease in type 2 diabetes
10.1056/nejmoa1515920 · 2016 · External reference
Canagliflozin and cardiovascular and renal events in type 2 diabetes
10.1056/nejmoa1611925 · 2017 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
Cardiovascular and renal outcomes with empagliflozin in heart failure
10.1056/nejmoa2022190 · 2020 · External reference
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · 2021 · External reference
2022 AHA/ACC/HFSA Guideline for the management of heart failure
10.1016/j.cardfail.2022.02.010 · 2022 · External reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020 · External reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023 · External reference
Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
10.1161/circulationaha.117.028268 · 2018 · External reference
Arachidonic acid metabolism and kidney inflammation
10.3390/ijms20153683 · 2019 · External reference
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
10.1038/s41392-020-00443-w · 2021 · External reference
Effects of arachidonic acid metabolites on cardiovascular health and disease
10.3390/ijms222112029 · 2021 · External reference
Epoxyeicosanoids in hypertension
10.33549/physiolres.934291 · 2019 · External reference
20-HETE signals through G-protein-coupled receptor GPR75 (G(q)) to affect vascular function and trigger hypertension
10.1161/circresaha.116.310525 · 2017 · External reference
20-HETE and hypertension
10.1161/hypertensionaha.124.21718 · 2024 · External reference
2020 International Society of Hypertension Global Hypertension Practice Guidelines
10.1161/hypertensionaha.120.15026 · 2020 · External reference
Targeting ROS-dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson’s disease rat model
10.1021/acschemneuro.0c00722 · 2021 · External reference
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
10.1186/s12890-022-01939-7 · 2022 · External reference
Animal studies on medicinal herbs: predictability, dose conversion and potential value
10.1002/ptr.4966 · 2014 · External reference
Systematic metabolomic analysis of eicosanoids after omega-3 polyunsaturated fatty acid supplementation by a highly specific liquid chromatography-tandem mass spectrometry-based method
10.1021/pr501200u · 2015 · External reference
Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat
10.1159/000189154 · 1996 · External reference
Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation
10.1146/annurev.pharmtox.45.120403.100045 · 2005 · External reference
20-HETE in the regulation of vascular and cardiac function
10.1016/j.pharmthera.2018.07.004 · 2018 · External reference
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
10.2337/dc14-1096 · 2015 · External reference
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
10.1186/s12933-017-0511-0 · 2017 · External reference
SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection
10.1016/j.jacbts.2019.11.007 · 2020 · External reference
Sodium-glucose cotransporter 2 inhibitor canagliflozin antagonizes salt-sensitive hypertension through modifying transient receptor potential channels 3 mediated vascular calcium handling
10.1161/jaha.121.025328 · 2022 · External reference
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
10.1111/j.1464-5491.2009.02894.x · 2010 · External reference
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
10.1111/dom.12322 · 2014 · External reference
Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
10.3389/fcvm.2022.999254 · 2022 · External reference
Metabolic and hepatic effects of empagliflozin on nonalcoholic fatty liver Mice
10.2147/dmso.s422327 · 2023 · External reference
The CYP/20-HETE/GPR75 axis in hypertension
10.1016/bs.apha.2022.02.003 · 2022 · External reference
Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury
10.1038/ki.2010.377 · 2011 · External reference
Conflicting roles of 20-HETE in hypertension and renal end organ damage
10.1016/j.ejphar.2018.06.010 · 2018 · External reference
Arachidonic acid intake promotes hypertension and target-organ fibrosis through CYP4A-mediated 20-HETE overproduction: integrated evidence from human and animal studies
10.1080/10641963.2025.2611130 · 2026 · External reference
SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases
10.1210/endocr/bqab079 · 2021 · External reference
Cardiorenal protection of SGLT2 inhibitors—perspectives from metabolic reprogramming
10.1016/j.ebiom.2022.104215 · 2022 · External reference
Advances in targeted treatment of ferroptosis in diabetic kidney disease with SGLT2 inhibitors
10.1186/s13098-026-02193-1 · 2026 · External reference
Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway
10.1016/j.freeradbiomed.2022.12.088 · 2023 · External reference
In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia
10.3390/ijms222111513 · 2021 · External reference
Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling
10.1080/0886022x.2025.2546624 · 2025 · External reference
High-fat diet-induced obesity and insulin resistance in CYP4a14(-/-) mice is mediated by 20-HETE
10.1152/ajpregu.00125.2018 · 2018 · External reference
Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods
10.1111/j.1748-1716.1984.tb00133.x · 1984 · External reference
Amplified respiratory-sympathetic coupling in the spontaneously hypertensive rat: does it contribute to hypertension?
10.1113/jphysiol.2008.165902 · 2009 · External reference
Role of the sympathetic nervous system in human hypertension
10.1097/00004872-199816121-00019 · 1998 · External reference
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
10.1016/j.jjcc.2017.12.004 · 2018 · External reference
Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states
10.1038/s41440-025-02216-w · 2025 · External reference
Dapagliflozin attenuates sympathetic and pressor responses to stress in young prehypertensive spontaneously hypertensive rats
10.1161/hypertensionaha.122.19177 · 2022 · External reference
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
10.1016/j.jash.2017.07.005 · 2017 · External reference
Animal models of hypertension: a scientific statement from the American Heart Association
10.1161/hyp.0000000000000090 · 2019 · External reference
Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects
10.1016/j.yjmcc.2022.03.005 · 2022 · External reference
